A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg) and Standard Dose ARA-C for Patients With Relapsed Acute Myeloid Leukemia (AML).
Phase of Trial: Phase II
Latest Information Update: 13 Jan 2012
At a glance
- Drugs Cytarabine (Primary) ; Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Jan 2012 Actual patient number is 33 according to ClinicalTrials.gov.
- 13 Jan 2012 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.